{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:24:39Z","timestamp":1784247879672,"version":"3.55.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Cancer-associated thrombosis (CAT) is a frequent and severe complication of malignancy. Although patients undergo anticoagulation, risks of recurrent venous thromboembolism (VTE) and major bleeding (MB) remain substantial, but data are limited according to specific tumor sites and in patients with frailty. Our objective was to evaluate 6-month incidences of recurrent VTE, MB, and death in patients with CAT treated with tinzaparin, and to assess the influence of tumor site and frailty on these risks. Individual patient-level data from 1413 patients were pooled from 3 prospective cohort studies and the tinzaparin arm of a randomized controlled trial. Frailty was defined as age of \u226575 years, creatinine clearance of &amp;lt;50 mL\/min, body weight of \u226450 kg, or Eastern Cooperative Oncology Group performance status of \u22652. Cumulative incidences were estimated using Kalbfleisch and Prentice method and plotted to illustrate the benefit-risk balance by tumor site and frailty. At 6 months, cumulative incidences of recurrent VTE and MB were 6.2% and 3.4%, respectively. Recurrent VTE incidence surpassed MB incidence in gastrointestinal, lung, genitourinary, and gynecological cancers, whereas MB risk exceeded VTE risk in breast cancer. Among patients with frailty criteria, recurrent VTE risk increased with the number of frailty factors, whereas MB remained relatively stable. In patients with CAT receiving tinzaparin, VTE recurrence, unlike bleeding risk, varies according to tumor site and patient frailty. In frail patients with CAT treated with standard full-dose tinzaparin, these findings do not support routine dose modification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019247","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T20:54:11Z","timestamp":1771448051000},"page":"3292-3300","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Complications in patients with cancer-associated thrombosis on tinzaparin by cancer site and frailty: a pooled analysis"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-7880","authenticated-orcid":false,"given":"Isabelle","family":"Mah\u00e9","sequence":"first","affiliation":[{"name":"1Paris Cit\u00e9 University, Paris, France"},{"name":"2Department of Internal Medicine, Louis Mourier Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"},{"name":"3Team Endotheliopathy and Hemostasis Disorders, Paris Cardiovascular Research Center, INSERM UMR-S970, Paris, France"},{"name":"4F-CRIN INNOVTE Network, Saint-\u00c9tienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-3666","authenticated-orcid":false,"given":"C\u00e9line","family":"Chapelle","sequence":"additional","affiliation":[{"name":"5INSERM Unit\u00e9 1059, Sant\u00e9 Ing\u00e9nierie Biologie Saint-\u00c9tienne, Mines Saint-\u00c9tienne, Universit\u00e9 Jean Monnet, Saint-\u00c9tienne, France"},{"name":"6Service de Pharmacologie Clinique, CHU de Saint-\u00c9tienne, Saint-\u00c9tienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Girard","sequence":"additional","affiliation":[{"name":"4F-CRIN INNOVTE Network, Saint-\u00c9tienne, France"},{"name":"7D\u00e9partement de Pneumologie, Institut Mutualiste Montsouris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4125-3376","authenticated-orcid":false,"given":"Luis","family":"Jara-Palomares","sequence":"additional","affiliation":[{"name":"8Medical Surgical Unit of Respiratory Diseases, Instituto de Biomedicina de Sevilla, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-6681","authenticated-orcid":false,"given":"Agnes Y. Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"9The University of British Columbia, Vancouver, BC, Canada"},{"name":"10BC Cancer, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-8391","authenticated-orcid":false,"given":"Olivier","family":"Sanchez","sequence":"additional","affiliation":[{"name":"1Paris Cit\u00e9 University, Paris, France"},{"name":"3Team Endotheliopathy and Hemostasis Disorders, Paris Cardiovascular Research Center, INSERM UMR-S970, Paris, France"},{"name":"4F-CRIN INNOVTE Network, Saint-\u00c9tienne, France"},{"name":"11Service de Pneumologie et Soins Intensifs, H\u00f4pital Europ\u00e9en Georges Pompidou, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Meyer","sequence":"additional","affiliation":[{"name":"4F-CRIN INNOVTE Network, Saint-\u00c9tienne, France"},{"name":"11Service de Pneumologie et Soins Intensifs, H\u00f4pital Europ\u00e9en Georges Pompidou, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1511-0555","authenticated-orcid":false,"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[{"name":"4F-CRIN INNOVTE Network, Saint-\u00c9tienne, France"},{"name":"5INSERM Unit\u00e9 1059, Sant\u00e9 Ing\u00e9nierie Biologie Saint-\u00c9tienne, Mines Saint-\u00c9tienne, Universit\u00e9 Jean Monnet, Saint-\u00c9tienne, France"},{"name":"12Service de M\u00e9decine Vasculaire et Th\u00e9rapeutique, CHU Saint-\u00c9tienne, H\u00f4pital Nord, Saint-\u00c9tienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6197-8668","authenticated-orcid":false,"given":"Silvy","family":"Laporte","sequence":"additional","affiliation":[{"name":"4F-CRIN INNOVTE Network, Saint-\u00c9tienne, France"},{"name":"5INSERM Unit\u00e9 1059, Sant\u00e9 Ing\u00e9nierie Biologie Saint-\u00c9tienne, Mines Saint-\u00c9tienne, Universit\u00e9 Jean Monnet, Saint-\u00c9tienne, France"},{"name":"6Service de Pharmacologie Clinique, CHU de Saint-\u00c9tienne, Saint-\u00c9tienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"3","key":"2026051211213438100_bib1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"issue":"2","key":"2026051211213438100_bib2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"7","key":"2026051211213438100_bib3","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"issue":"17","key":"2026051211213438100_bib4","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"2026051211213438100_bib5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"Mah\u00e9","year":"2017","journal-title":"Am J Med"},{"issue":"5","key":"2026051211213438100_bib6","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1055\/s-0041-1735194","article-title":"Apixaban and dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer","volume":"122","author":"Agnelli","year":"2022","journal-title":"Thromb Haemost"},{"issue":"9","key":"2026051211213438100_bib7","doi-asserted-by":"crossref","first-page":"102101","DOI":"10.1016\/j.jacadv.2025.102101","article-title":"Variation in venous thromboembolism outcomes based on primary cancer site: a RIETE Registry analysis","volume":"4","author":"Trujillo-Santos","year":"2025","journal-title":"JACC Adv"},{"issue":"1","key":"2026051211213438100_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1477-9560-11-21","article-title":"Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies","volume":"11","author":"Prins","year":"2013","journal-title":"Thromb J"},{"issue":"2","key":"2026051211213438100_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/rth2.12036","article-title":"Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism","volume":"1","author":"Moustafa","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2026051211213438100_bib10","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1055\/s-0039-1683970","article-title":"Direct oral anticoagulants or standard anticoagulant therapy in fragile patients with venous thromboembolism","volume":"3","author":"L\u00f3pez-N\u00fa\u00f1ez","year":"2019","journal-title":"TH Open"},{"issue":"1","key":"2026051211213438100_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.acvd.2023.11.009","article-title":"Management of cancer-associated thromboembolism in vulnerable population","volume":"117","author":"Laporte","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"2026051211213438100_bib12","doi-asserted-by":"crossref","first-page":"e103278","DOI":"10.1016\/j.rpth.2025.103278","article-title":"The Ottawa score for prediction of recurrent venous thromboembolism in cancer patients treated with tinzaparin: an individual patient data meta-analysis","volume":"10","author":"Chapelle","year":"2026","journal-title":"Res Pract Thromb Haemost"},{"issue":"1","key":"2026051211213438100_bib13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/a-1486-7497","article-title":"Failure of the Ottawa score to predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE Cohort study","volume":"122","author":"Girard","year":"2022","journal-title":"Thromb Haemost"},{"key":"2026051211213438100_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study","volume":"157","author":"Jara-Palomares","year":"2017","journal-title":"Thromb Res"},{"issue":"4","key":"2026051211213438100_bib15","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jaccao.2022.07.008","article-title":"Performance Status and Long-Term Outcomes in Cancer-Associated Pulmonary Embolism: Insights From the Hokusai-VTE Cancer Study","volume":"4","author":"Farmakis","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"suppl 1","key":"2026051211213438100_bib16","first-page":"4018-4018","article-title":"Performance status, cancer-associated thrombosis, and bleeding: a post-hoc analysis of the AVERT trial","volume":"144","author":"Potere","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026051211213438100_bib17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026051211213438100_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.acvd.2023.11.010","article-title":"Anticoagulant treatment of cancer-associated thromboembolism","volume":"117","author":"Mah\u00e9","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"issue":"12","key":"2026051211213438100_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.acvd.2025.07.007","article-title":"The management of cancer-associated thromboembolism: proposals from the French multidisciplinary INNOVTE CAT Working Group","volume":"118","author":"Mah\u00e9","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"issue":"4","key":"2026051211213438100_bib20","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1160\/TH06-09-0513","article-title":"Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study","volume":"97","author":"Mah\u00e9","year":"2007","journal-title":"Thromb Haemost"},{"issue":"10","key":"2026051211213438100_bib21","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1016\/j.jtha.2024.07.006","article-title":"Tinzaparin, an alternative to subcutaneous unfractionated heparin, in patients with severe and end-stage renal impairment: a retrospective observational single-center study","volume":"22","author":"Gouin-Thibault","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026051211213438100_bib22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40256-019-00382-0","article-title":"Tinzaparin sodium pharmacokinetics in patients with chronic kidney disease: practical implications","volume":"20","author":"Helfer","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026051211213438100_bib23","doi-asserted-by":"publisher","DOI":"10.1055\/a-2740-1841","article-title":"Tinzaparin pharmacokinetics in patients with cancer: a comparative modeling study","author":"Delavenne","year":"25  2025","journal-title":"Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3292\/2518940\/blooda_adv-2025-019247-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3292\/2518940\/blooda_adv-2025-019247-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:21:44Z","timestamp":1778599304000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3292\/566662\/Complications-in-patients-with-cancer-associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019247","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,5,12]]}}}